Solutions Through Immunology

Advancing Vaccines and BioTherapeutics

Our GMP, Your IND

Advancing Vaccines and BioTherapeutics

Breakthroughs Delivered

Advancing Vaccines and BioTherapeutics

About ABL

ABL provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market.

Learn More
Spotlight

Aushon BioSystems and ABL, Inc. Announce Adoption of the Cira™ Platform for Multiplex and Ultrasensitive Biomarker Testing

ABL strengthens biomarker capabilities for a wide range of disease states with the Cira platform.

Read More

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

ABL announced today it has been awarded the recompetition of the contract for “Preclinical Development Support” by the Division of AIDS (DAIDS) within the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). The contract will run for a total of seven years with a maximum funding level of $318 million.

Read More

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

ABL is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a new, fully automated vial filling system.

Read More

ABL, Inc. Earned GCLP Certificate of Accreditation

In Q1 2017, ABL was awarded a certificate of full accreditation after satisfactorily implementing the requirements set out in the Good Clinical Laboratory Practice (GCLP), an international standard developed by the World Health Organization (WHO) to close the gap between preclinical GLP and GCP testing.

Learn More